A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Visionweb & Neurolens Collaborate to Increase Prism Specificity

Through VisionWeb's ordering platform, prism can now be entered to the 1/100th prism diopter

What To Know

  • Mike Bonacci, Director of Integrations at VisionWeb says, “We are on a mission to make it easier for people in the eyecare industry to do their jobs, and we will continue to pioneer technology that enables eyecare providers to more efficiently conduct business and meet the needs of their patients.
  • Ongoing research from a myriad of sources has indicated that at least two out of three patients experience the symptoms of eye misalignment, and the rapid acceleration in remote working and learning over the past two years has undoubtedly led to a rise in this figure.

Ongoing research from a myriad of sources has indicated that at least two out of three patients experience the symptoms of eye misalignment, and the rapid acceleration in remote working and learning over the past two years has undoubtedly led to a rise in this figure. Optical prisms are one of the most commonly employed treatment modalities to correct these binocular vision issues.

As such, technological innovations in this space will become increasingly important to the future of eyecare. In order to ensure that eyecare providers are able to meet these growing challenges, Neurolens and VisionWeb have worked together to expand the prism field from 1/4th prism diopter to 1/100th prism diopter when placing orders through VisionWeb’s ordering platform.

“At Neurolens, we strongly believe that the eyecare industry must evolve beyond visual acuity to own the visual comfort space as well,” says Pierre Bertrand, Chief Executive Officer of Neurolens. “A large and growing percentage of the population is suffering from the symptoms of binocular vision issues—some on a daily basis—and Neurolenses provide proven relief for these patients. We are proud to collaborate with an industry leader like VisionWeb to ensure that eyecare providers can prescribe optical prism to the specificity required to meet the needs of today’s patients.”

This expanded prism range will allow Neurolens providers to take advantage of the highly accurate measurements from the Neurolens Measurement Device (NMD) and Neurolens Measurement Device, Gen 2 (NMD2) and prescribe precise prism measurements for their patients. “We are learning more every day about how small amounts of prism can create tremendous symptom relief for patients,” says Vivek Labhishetty BSc Optometry, MSc, PhD, Director of Clinical Research for Neurolens. “This creates an imperative to ensure prism measurements can be entered with a high degree of specificity to maximize the number of patients that can be helped by this technology.”

Mike Bonacci, Director of Integrations at VisionWeb says, “We are on a mission to make it easier for people in the eyecare industry to do their jobs, and we will continue to pioneer technology that enables eyecare providers to more efficiently conduct business and meet the needs of their patients. This development sends yet another signal that VisionWeb will make every effort to remain on the forefront of emerging trends in practice management and patient care.”

SourceNeurolens
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.
SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.

By using this website you agree to accept Medical Device News Magazine Privacy Policy